Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Journal of Biological Chemistry|February 28, 2003
Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin functionNatalia V Gorlatova, Hassan Elokdah, Kristi Fan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 2009
Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injuryRym Abderrahmani, Agnès François, Valérie Buard, et al.
Journal of Medicinal Chemistry|June 25, 2004
Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterizationHassan Elokdah, Magid Abou-Gharbia, James K Hennan, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effectsHassan M Elokdah, Gregory S Friedrichs, Sie Yearl Chai, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 9, 2008
p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidineXiaomin Deng, Jingtao Lu, Lois D Lehman-McKeeman, et al.
The Journal of Biological Chemistry|February 6, 2007
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitorNatalia V Gorlatova, Jacqueline M Cale, Hassan Elokdah, et al.
Journal of Molecular and Cellular Cardiology|August 2, 2015
Comparative effects of urocortins and stresscopin on cardiac myocyte contractilityCatherine A Makarewich, Constantine D Troupes, Sarah M Schumacher, et al.
Biochemical and Biophysical Research Communications|November 19, 2003
WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregationDavid L Crandall, James K Hennan, Hassan Elokdah, et al.
Molecular Pharmacology|July 12, 2007
Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of actionStephen J Gardell, Julie A Krueger, Thomas A Antrilli, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 4, 2004
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodelingAlec D Weisberg, Francisco Albornoz, Jane P Griffin, et al.
Pageof 2